IQWiG assesses Constella, Jetrea
Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) issued preliminary benefit assessments for Constella linaclotide from Almirall S.A. (Madrid:ALM) and Jetrea ocriplasmin from ThromboGenics N.V. (Euronext:THR). IQWiG said Constella has "no additional benefit" for irritable bowel syndrome with constipation (IBS-C) vs. a change in diet and symptom-specific treatment, the comparator requested by Germany's Federal Joint Committee (G-BA). IQWiG said the company did not submit "relevant" data. Almirall has exclusive rights to the guanylate cyclase C ( GCC; GUCY2C) agonist from Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in Europe and the Commonwealth of Independent States (CIS).
Separately, IQWiG said Jetrea provides additional benefit vs. watchful waiting in some patients with vitreomacular traction (VMT). The institute said Jetrea has "major" benefit in VMT patients with mild visual impairment and "significant" benefit in patients with moderate visual impairment. IQWiG said no data were provided for patients with asymptomatic or severe VMT. Alcon Inc., the ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN), has ex-U.S. commercialization rights to the injectable recombinant microplasmin, a truncated form of the natural human protein plasmin. ...